CYP26A1 Is a Novel Cancer Biomarker of Pancreatic Carcinoma: Evidence from Integration Analysis and In Vitro Experiments

Figure 6

Immune infiltration analysis of CYP26A1. Notes: (a) ssGSEA algorithm was used to quantify the immune infiltration difference in low and high CYP26A1 patients. (b)–(d) Estimate algorithm was used to quantify the immunescore, stromalscore, and estimatescore of PC patients.

(a)

(b)

(c)

(d)